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OBJECTIVES: Chronic Myeloid Leukemia (CML) is a rare tumor. In France, the 
incidence is estimated to be 1/105 inhabitants/years. Imatinib has been approved to 
treat CML since 2002 but information on routine use, safety and efﬁcacy in unselected 
“real life” setting is lacking. An observational cohort (LMC) in France was designed 
to provide data on survival, safety, treatment patterns and quality of life. METHODS: 
LMC is nationwide, multicenter, observational study on CML patients treated with 
Imatinib between the availability on the French Market and the end of the 2008. 
Centers were randomly selected in national ﬁles of oncologists, hematologists and 
internists. The planned follow-up duration was ﬁve years. A case report form had to 
be completed at inclusion and during each follow-up visits. Quality of life was assessed 
using QLQ-C30 and SF36 questionnaires. RESULTS: Thrity-nine on 55 selected 
centers enrolled at least one patient and 387 patients were included (as of June 2009). 
The median age of disease onset was 59 years. At diagnosis 94% of patients were in 
a chronic phase and had a low or intermediate Sokal (74%). Before Imatinib, 49% 
of patients received hydroxuyrea and 16% received interferon. Imatinib initiation was 
SPC conform: 400 mg per day for 95% of patients. Median treatment duration at 
inclusion was 25 months. 11% of patients with a follow-up of 1 year iin the study 
had a modiﬁcation of te Imatinib dose. Rate of complete molecular response was 37%. 
With a median follow-up of 3.6 years, 2 years overall survival from ﬁrst treatment 
with Imatinib was 96.2% (IC95%: [94.1%–98.4%]). Quality of life of patients was 
stable. CONCLUSIONS: LMC study is still on ongoing. Current results conﬁrm previ-
ous published data on survival in CML treated with Imatinib in an unselected cohort 
of patients outside a clinical trial.
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OBJECTIVES: The occurrence of cervical cancer in the Western Trans-Danubian 
region of Hungary is outstandingly high. Cervical screening upon individual invitation 
was launched within the frameworks of a National Program in Hungary in 2003. In 
the course of our study we have sought an answer to the question why women do not 
take the opportunity offered, why they fail to appear on screening examinations. 
METHODS: The sample population of the cross-section survey involved women 
between the age of 18–65 from the city of Zalaegerszeg with a convenient sampling 
method. In addition to a motivational scale of 21 variables, our questionnaire included 
demographical aspects, the subjective judgment of health status and one group of the 
questions were related to the factors of appearing on a gynecological screening exami-
nation. RESULTS: A total of 51.3% of the women appear on the annual screenings 
regularly from among the 520 women assessed. In the course of assessment of the 
primary component, the 21 variables of our motivational scale were grouped around 
six theoretical sub-concepts. Cronbach Alfa coefﬁciency was 0.8257. Non-appearance 
on the examinations due to fear has shown a signiﬁcant relationship with age, marital 
status and level of education (p  0.05). CONCLUSIONS: In order to further decrease 
national mortality rates an adequately motivated, continuous performance of cancer 
screening remains essential. For cervical cancer check-ups a separate concept and 
infrastructure is provided on behalf of our health administration. The weakness of 
this system however is connected to the low rate of appearance of the population, 
which in accordance with the above results is also supported by statistical data, is 
inﬂuenced by fear, the injury of the personal intimacy the sense of an uncomfortable 
examination and long waiting times as well. At the same time we must note that a 
majority of women feeling responsible for their own health conditions do appear on 
screening examinations.
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SYSTEMATIC REVIEW OF THE EFFICACY AND SAFETY OF IMIQUIMOD 
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OBJECTIVES: The aim of the review was to evaluate the efﬁcacy and safety of 
imiquimod 5% cream compared with vehicle for treating superﬁcial basal cell carci-
noma. METHODS: The analysis was performed in accordance with the rules of 
 systematic review, based on the Cochrane Collaboration (Cochrane Reviewer’s Hand-
book) guidelines and the Health Technology Assessment Agency in Poland (AOTM) 
recommendations. RESULTS: Two multicenter, vehicle-controlled, randomized clini-
cal trials of high quality were identiﬁed according to predeﬁned selection criteria. 
Treatment with imiquimod 5% cream once a day, 3 times per week resulted in sig-
niﬁcantly greater complete response rate than vehicle in the period of 6 as well as 12 
weeks. Probability of achieving the complete response rate (no histological evidence 
of superﬁcial basal cell carcinoma in the excised post–treatment target tumor tissue) 
was signiﬁcantly greater for imiquimod 5% cream than vehicle and amounted to 18.2 
(95% CI: 4.19; 84.84) and 146.14 (95% CI: 69.3; 323.75) respectively at 12 and 6 
weeks after treatment. The incidence of adverse events during the treatment period 
such as application site reaction including itching, pain and tenderness at the target 
tumor site and local skin reaction such as erythema, scabbing, were more frequently 
recorded in the group of subjects who received imiquimod 5% cream in comparison 
with the vehicle group. CONCLUSIONS: Imiquimod 5% cream appears to be effective 
in the treatment of superﬁcial basal cell carcinoma. A 3 times a week dosing demon-
strates high efﬁcacy results with acceptable safety proﬁle, during the 6 as well as 12-
week period.
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OBJECTIVES: In The Netherlands, additional funding of expensive hospital drugs 
requires an assessment of real-world cost-effectiveness. We explored the extent to 
which real-world data for bortezomib in relapsed or refractory multiple myeloma 
(MM) patients provides a valid estimate of its real-world incremental effectiveness. 
METHODS: A retrospective study was conducted by collecting data from medical 
records of Dutch MM patients. Validity of the real-world incremental effectiveness 
estimate was assessed by comparing real-world bortezomib patients (N  72) ﬁrst to 
bortezomib patients in the APEX trial (N  333) in relation to baseline prognostic 
factors and treatment outcomes, and secondly to real-world patients not receiving 
bortezomib (N  67) in relation to baseline prognostic factors. RESULTS: Com-
parisons between all groups in relation to the baseline prognostic factors serum B2-
microglobulin, c-reactive protein, creatinine clearance and performance status were 
restricted due to frequent missing values. Real-world bortezomib patients did not 
differ from trial-based patients in previous treatment proﬁle and some treatment out-
comes such as time-to-progression (7 vs. 6 months), complete or partial response (39% 
vs. 38%) and minor response (13% vs. 8%). However, real-world bortezomib patients 
differed from trial-based patients in the frequency of treatment responses stable (3% 
vs. 43%) and progressive disease (19% vs. 7%), and less often received bortezomib 
monotherapy. At baseline, median time-to-ﬁrst-progression was signiﬁcantly longer in 
real-world bortezomib patients (28 vs. 23 months) compared to real-world patients 
never receiving bortezomib, possibly due to being more likely to have received prior 
maintenance therapy (55% vs. 39%). CONCLUSIONS: Preliminary results suggest 
that the real-world effectiveness of bortezomib for MM may not differ greatly from 
trial-based efﬁcacy, but that a valid incremental estimate may be difﬁcult to obtain. 
The challenge of obtaining relevant comparator groups and limited data available in 
patient charts compromise the ability to obtain a valid real-world estimate, underscor-
ing the need for an alternative study design.
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CHRONIC MYELOID LEUKAEMIA (CML) WITH IMATINIB MESYLATE 
AND BONE MARROW TRANSPLANTATION (BMT)
Sladkevicius E1, Coombs J2, Guest JF1
1Catalyst Health Economics Consultants, Northwood, Middlesex, UK, 2Novartis 
Pharmaceuticals, East Hanover, NJ, USA
OBJECTIVES: While BMT is the only potentially curative treatment for CML, patient 
eligibility is limited and morbidity risks are common. Imatinib (IM) is the current           
treatment of choice for many patients with CML. This literature review compared the 
clinical and economic outcomes attributable to ﬁrst-line treatment for chronic phase 
CML with IM and BMT. METHODS: A systematic review of published literature 
was undertaken using Medline. The search terms focused on IM and BMT as well as 
epidemiology, morbidity, mortality, quality of life and cost-effectiveness. The search 
of English language papers was undertaken from 1997 to the present. A manual        
 literature search was also undertaken, identifying further articles from citations in 
published papers. RESULTS: Twenty-nine relevant publications were identiﬁed     
 providing data on at least 4,931 IM-treated patients and 1,699 patients who received      
BMT (sample size was omitted in some instances). The probability of mortality in 
year 1 was estimated to be ^28% and 0% among those who received BMT and IM 
respectively. Use of IM relative to BMT in chronic phase CML is also expected to    
lead to increased rates of complete haematologic and cytogenetic response, higher 
short-term overall survival and event-free survival. Moreover, IM is associated with 
fewer haematological complications such as chronic and acute graft versus host disease 
and a greater proportion of IM-treated patients are expected to be free from 
disease progression. IM treatment compared with transplant resulted in an incremental 
cost saving of $5000 per surviving patient after approximately 2–4 years of follow-up. 
CONCLUSIONS: Published evidence supports the use of IM in patients eligible for 
transplant. In the short-term, imatinib appears to be a clinically more effective, better 
tolerated, cost-effective treatment compared to BMT in the management of chronic  
CML. However, longer-term published data are lacking.
